Remedium Bio announces the publication of preclinical data demonstrating the performance of its adjustable dose gene therapy platform – Prometheus™
Posted:
Prometheus™ was specifically designed as a subcutaneously injected gene delivery system, utilizing the same route of administration as most current therapeutic biologics. Remedium is applying the Prometheus™ platform technology to the development of its lead candidate RMD1202, a single injection disease-modifying treatment for type 2 diabetes and obesity.
A new AI framework can detect neurological disorders by analyzing speech with over 90% accuracy. The model, called CTCAIT, captures subtle patterns in voice that may indicate early symptoms of diseases like Parkinson’s, Huntington’s, and Wilson disease.
Read more here.
Attendees
Sponsors and Exhibitors
Agenda 2025
Contact us